Indian Pharma Billionaires Pile Into Generic Weight-Loss Drugs, Sparking Regulatory Scrutiny

Last week’s expiry of the patent for semaglutide—the active ingredient in Novo Nordisk’s blockbuster drugs Wegovy and Ozmepic that are used to treat both diabetes and obesity—unleashed a flurry of launches of low-cost generic versions by some of India’s biggest pharma companies.

Go to News Site